Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Valion Bio, Inc.

NASDAQ: VBIO · Life Sciences · 14 alerts · CIK 1787740

Share price
$0.5290Close, Nov 16
Market cap
$11.7M
Shares outstanding
22.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Valion Bio, Inc. filings on SEC EDGAR ↗

6:04 AM ET 8-K
Capital Raise

Valion Bio Capital Raise of $700K

Valion Bio, Inc. completed a $700,000 closing under its existing Series B Preferred Purchase Agreement with 3i, LP, issuing 700 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 21,539 shares of common stock. As part of the agreement, the company committed to filing a registration statement for the resale of the underlying common shares within 30 days and extended the outside date for future closings to December 9, 2027.

Value
$700K
Counterparty
3i, LP
7:46 AM ET 8-K
Clinical Trial Data

Valion Bio Clinical Trial Data

Valion Bio announced positive final safety data from a NIAID-funded study of its lead biologic candidate, Entolimod, conducted by the Armed Forces Radiobiology Research Institute (AFRRI). The study found no evidence of treatment-related toxicity or hematologic disruption in mice, supporting the advancement to a fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure.

Counterparty
Armed Forces Radiobiology Research Institute
Term
14-day observation period
6:03 AM ET 8-K
Capital Raise

Valion Bio Capital Raise of $4.77M

Valion Bio, Inc. entered into side letters to issue Series B and Series C Preferred Shares and warrants for total proceeds of approximately $4.77 million. The transaction includes a $50,000 Series B closing with 3i, LP and a $4.72 million Series C closing with existing purchasers, part of which satisfies overdue cash true-up obligations.

Value
$4.77M
Counterparty
3i, LP
8:00 AM ET 8-K
M&A Deal

Valion Bio M&A Deal Update

Valion Bio has received unsolicited acquisition inquiries from third parties regarding its wholly owned CDMO subsidiary, Velocity Bioworks. The company has retained an investment bank to evaluate strategic options, including a potential sale, while prioritizing the retention of manufacturing rights for its lead drug candidate, Entolimod.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.